A phase I/II dose-escalation study of exisulind and docetaxel in patients with hormone-refractory prostate cancer

Christopher W. Ryan, Walter M. Stadler, Nicholas J. Vogelzang

    Research output: Contribution to journalArticlepeer-review

    15 Scopus citations

    Fingerprint

    Dive into the research topics of 'A phase I/II dose-escalation study of exisulind and docetaxel in patients with hormone-refractory prostate cancer'. Together they form a unique fingerprint.

    Medicine & Life Sciences